Search

Researchers at the University of the Witwatersrand in South Africa have highlighted the challenges of managing Medullary Thyroid Carcinoma (MTC), a rare and aggressive form of thyroid cancer. They emphasize the need for personalized care due to the complexities of MTC and propose the integration of Holomics and Artificial Intelligence (AI) to enhance diagnostic processes and treatment plans. This innovative approach aims to improve global collaboration, equitable healthcare solutions, and ultimately transform the landscape of MTC treatment, aligning with the United Nations Sustainable Development Goal 3. [Extracted from the article]

A recent study from Emory University examined adherence to American Thyroid Association guidelines for medullary thyroid cancer (MTC) treatment. The research found that improved adherence to these guidelines may lead to better overall survival rates for patients with MTC. Factors associated with discordant treatment included gender, age, facility type, and proximity to treatment center. The study analyzed data from 2009 to 2015 and concluded that adherence to guidelines could positively impact patient outcomes. [Extracted from the article]

Researchers at Hacettepe University School of Medicine have developed a new method, lymph node ACTH washout, to identify the source of ACTH production in a case of metastatic medullary thyroid carcinoma. This method was used on a 23-year-old male with Cushing's syndrome resulting from medullary thyroid cancer, leading to a diagnosis and subsequent treatment. The study highlights the potential effectiveness of lymph node ACTH washout as a diagnostic tool in cases of ACTH-dependent Cushing syndrome. [Extracted from the article]

The article discusses a case study from Rutgers University on metastatic medullary thyroid carcinoma presenting as an incidental posterior mediastinal mass. The research emphasizes the importance of testing for calcitonin in masses with neuroendocrine features to enable earlier detection of MTC and improve prognosis. This study highlights the significance of thorough testing for accurate diagnosis and treatment of rare neuroendocrine tumors like MTC. [Extracted from the article]

A recent study on medullary thyroid cancer conducted at the Affiliated Hospital of Nanjing University of Chinese Medicine in China highlights the challenges posed by this rare but aggressive form of thyroid malignancy. The research focuses on the molecular genetics of medullary thyroid cancer, particularly the role of the RET gene and the RAS gene family, offering insights into potential therapeutic targets and novel biomarkers. The study emphasizes the importance of precision therapies and the need for further research in this field to improve clinical practice and patient outcomes. [Extracted from the article]

A recent report from researchers at the Cancer Hospital in Beijing, China, highlights the use of a new imaging technique called Ga-68-TCR-FAPI PET-CT for detecting medullary thyroid carcinoma (MTC). The study compared the effectiveness of Ga-68-TCR-FAPI PET-CT with the currently approved F-18-FDG PET-CT in detecting MTC lesions. The results showed that Ga-68-TCR-FAPI PET-CT had a significantly higher detection rate and diagnostic accuracy compared to F-18-FDG PET-CT. This new imaging technique could improve the management and treatment decisions for MTC patients. [Extracted from the article]

A recent study conducted at Zhejiang Cancer Hospital focused on medullary thyroid cancer (MTC), a rare type of thyroid malignancy. The study found that MTC can be hereditary or sporadic, with different genetic mutations present in each case. Surgery is the standard treatment for early-stage MTC, while chemotherapy has shown limited effectiveness for metastatic MTC. However, targeted therapies for the RET gene have shown promise in increasing progression-free survival for patients with advanced MTC. The study also highlighted the need for further research on drug resistance and the development of novel therapeutic approaches. [Extracted from the article]

A recent study conducted at the Memorial Sloan-Kettering Cancer Center has found that the protein SEZ6 is highly expressed in medullary thyroid carcinoma (MTC), a type of thyroid cancer. SEZ6 has also been found in small cell lung carcinoma (SCLC) and is being targeted by a novel antibody drug conjugate called ABBV-011, which is currently in clinical trials for treating SCLC and neuroendocrine neoplasms, including MTC. The study suggests that SEZ6 could serve as a biomarker for MTC and that SEZ6-targeted therapy shows promise as a targeted treatment for MTC, even in cases without specific genetic mutations. [Extracted from the article]

A recent report from SRM Medical College Hospital and Research Centre in Tamil Nadu, India, discusses a case of medullary thyroid cancer. The patient, a 64-year-old male with uncontrolled type 2 diabetes mellitus and peripheral vascular disease, presented with a swelling on the right side of his neck. The swelling had slowly progressed over the past five years and was accompanied by palpable lymph nodes. Blood investigations revealed a reduced hemoglobin level, but thyroid function tests were normal. This case highlights the importance of considering thyroid carcinoma in patients with palpable lymph nodes. [Extracted from the article]

Recent findings from the University of Rochester provide new insights into medullary thyroid cancer (MTC). MTC is a rare primary neuroendocrine thyroid carcinoma that is distinct from other thyroid or neuroendocrine cancers. Most cases of MTC are sporadic, but it exhibits a high degree of heritability. The primary oncogenic drivers of MTC are RET mutations, and advances in molecular profiling have revealed druggable alterations. Surgery at an early stage is the only chance for a cure, but many patients present with or develop metastases. Biomarkers such as C-cell-specific calcitonin trajectory and structural doubling times are critical for prognosis and treatment decisions. Recent advances in active surveillance, regionally directed therapies, and systemic therapy with multi-kinase and RET-specific inhibitors have significantly improved outcomes for patients with MTC. [Extracted from the article]

A recent study conducted at the Cancer Hospital examined the survival rates of patients with medullary thyroid carcinoma (MTC) who did not achieve a biochemical cure after surgery. The study found that patients with high postoperative 1-month calcitonin (Ct) levels had a greater risk of mortality. Additionally, targeted therapy did not improve the overall survival of MTC patients with distant metastasis. These findings suggest that patients who do not achieve biochemical remission after surgery may be at an increased risk of death, and targeted therapy may not be effective in prolonging survival in certain cases. [Extracted from the article]

A recent report from the University of Colorado discusses new findings on medullary thyroid cancer (MTC), a hereditary cancer syndrome caused by germline-activating pathogenic variants in the RET proto-oncogene. The report focuses on the specific RET germline heterozygous variant K666N, which has been described in very few families. The researchers highlight the need for further understanding of the pathogenicity of this variant and the appropriate screening and treatment for asymptomatic carriers. The report includes a case study of a patient with the RET K666N variant who experienced cardiogenic shock and multi-organ failure. [Extracted from the article]

A study presented at the Annual Meeting of The European Association for the Study of Diabetes reveals that tirzepatide (TZP), a medication used to manage blood sugar levels and weight loss in individuals with type 2 diabetes (T2D), has a reassuring safety profile. The study compared TZP to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and found that TZP had similar gastrointestinal tolerability without an increased risk of pancreatitis, diabetic retinopathy, and medullary thyroid cancer. However, the study is limited by its observational nature and non-randomized comparisons, so caution should be exercised in interpreting the results. [Extracted from the article]

A recent bibliometric study conducted by researchers at the University of British Columbia focused on Medullary Thyroid Cancer (MTC). The study analyzed the most-cited publications in MTC research and highlighted the historical developments in this field. The analysis revealed a gradual increase in the number of publications on MTC over the years, with a focus on the genetic basis for MTC, targeted therapy, and guidelines. The study concluded that bibliometric analysis can help identify research frontiers in MTC. This research has been peer-reviewed and can be found in The American Journal of Surgery. [Extracted from the article]

A recent report from Yashoda Hospital discusses the rare occurrence of medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) in the same patient. The report describes the case of a 36-year-old male who presented with symptoms of headache, palpitations, and abdominal pain. After evaluation, the patient was found to have bilateral pheochromocytoma and MTC, as well as a RET proto-oncogene germline mutation. The patient underwent bilateral adrenalectomy and total thyroidectomy, and genetic analysis revealed a high-risk RET mutation. The report emphasizes the importance of early identification through genetic screening and prophylactic total thyroidectomy to prevent complications of aggressive MTC. [Extracted from the article]

A recent study conducted by researchers at Yonsei University College of Medicine in Seoul, South Korea, compared the diagnostic performance of preoperative calcitonin and procalcitonin tests for medullary thyroid cancer (MTC). MTC is a type of thyroid cancer with a relatively poor prognosis. The study found that both calcitonin and procalcitonin showed similar diagnostic utility for MTC, with high sensitivity and specificity. Depending on the patient's clinical status and laboratory environment, these tests can be used as complementary methods for detecting MTC. [Extracted from the article]

The article focuses on a patent application submitted for a novel cancer treatment involving GFR Alpha-4 chimeric antigen receptors. Topics include the increasing incidence of medullary thyroid carcinoma (MTC), the role of GFRa4 as a target for MTC diagnosis and therapy, and the development of new antibodies and chimeric antigen receptors to improve treatment efficacy.

The article from the University of Texas MD Anderson Cancer Center explores the Medullary Thyroid Cancer Collaborative Registry (MTCCoRe) and its effectiveness in representing the real-world population of medullary thyroid cancer patients. Topics discussed include differences in patient demographics and clinical characteristics compared to population-based registries, variations in treatment modalities, and the need for improved inclusion of underrepresented groups in future studies.

The article presents new findings from the University of Medicine and Pharmacy "Victor Babes" Timisoara on medullary thyroid carcinoma (MTC) in patients with Graves' disease. Topics discussed include the increased incidence of thyroid malignancies in Graves' disease patients, the case series of three women with MTC, and the recommendation for integrating calcitonin testing into standard diagnostic protocols.

A clinical trial has been launched to compare the diagnostic effects of two PET/CT scans, 68Ga-MGS5 and 68Ga-DOTATATE, on patients with medullary thyroid carcinoma (MTC). The trial aims to determine the effectiveness of these scans in detecting primary foci, lymph node metastasis, and distant metastasis of MTC, as well as their impact on the clinical staging of the disease. The study will enroll 20 patients and is being conducted at the First Hospital of Fujian Medical University in China. The trial is currently recruiting participants and is expected to be completed by July 2025. [Extracted from the article]

A recent study conducted at Radboud University Medical Center in the Netherlands investigated the use of digoxin to reinduce radioiodine uptake in patients with metastasized non-medullary thyroid carcinoma (NMTC) that is refractory to radioactive iodine (RAI). The study included eight patients who were treated with digoxin for three weeks, and their RAI uptake was compared before and after treatment. However, the results showed that digoxin treatment did not reinduce RAI uptake in these patients. This study highlights the challenges in optimizing studies aimed at restoring RAI uptake and its therapeutic efficacy through drug repurposing. [Extracted from the article]

A recent study conducted at Shanghai Sixth People's Hospital investigated the impact of primary tumor resection (PTR) on patients with distant metastasis medullary thyroid carcinoma (DMMTC). The study aimed to assess the benefits of PTR and identify optimal surgical indications. The research found that PTR significantly improves prognosis in selected DMMTC patients, with significant advantages in overall survival (OS) and disease-specific survival (DSS) for the surgical group. However, the decision to undergo PTR in other patients should be based on a comprehensive assessment of the disease, surgeon's experience, and family discussions for potential survival benefits. [Extracted from the article]

A clinical trial, NCT06530316, is currently underway in China to evaluate the effectiveness and safety of RET inhibitors as neoadjuvant therapy for locally advanced RET-altered thyroid cancer. The trial involves administering RET inhibitors to patients in a real-world setting, followed by surgical treatment for those eligible. The study aims to assess various outcomes, including resection rate, objective response rate, disease control rate, time to objective response, progression-free survival, overall survival, and adverse events. The document provides information about an FDA-regulated device product without disclosing the collaborators or investigators. The keywords associated with this article cover topics such as pharmaceuticals, surgery, genetics, clinical research, thyroid neoplasms, drugs and therapies, health and medicine, neoadjuvant therapy, combined modality therapy, clinical trials and studies, medullary thyroid carcinoma, and oncology - medullary thyroid cancer. [Extracted from the article]

A study conducted at the Hospital of the University of Pennsylvania examined the presentation and treatment of medullary thyroid cancer (MTC) and found disparities based on sex and race/ethnicity. The study analyzed data from the National Cancer Database and found that male and non-White patients with MTC were more likely to present with advanced disease. Additionally, Black patients were less likely to undergo guideline-concordant surgery. These findings highlight the need for further research and interventions to address these disparities in the management of MTC. [Extracted from the article]

A recent study conducted by researchers at the University of Sydney explores the molecular biology of medullary thyroid carcinoma (MTC) and its interaction with the immune system. The study found that MTC is primarily driven by specific pathogenic variants, resulting in a low tumor mutational burden and a limited number of tumor-associated neoantigens. This suggests that immunotherapy may not be effective in treating MTC. The study also highlights the efficacy of targeted tyrosine kinase inhibitors (TKIs) in comparison to multi-kinase inhibitors (MKIs) for MTC treatment. However, the use of TKIs may promote the survival of resistant tumor cells. [Extracted from the article]

A recent study conducted by Martin Luther-University Halle-Wittenberg in Germany compared the oncological features of sporadic and hereditary pediatric medullary thyroid cancer (MTC). The study found that sporadic MTC is extremely rare in infancy and childhood, and infrequent in adolescence. The researchers analyzed data from 1252 patients with MTC, of which only 4 pediatric patients had sporadic MTC. These patients had larger thyroid tumors and were more comparable to carriers of high-risk mutations in terms of extrathyroid extension and nodal metastases. The study concluded that sporadic MTC, although rare, presents with similar characteristics to hereditary MTC at diagnosis. [Extracted from the article]

A recent study conducted at the Medical University of Vienna in Austria examined the use of [18F]F-DOPA PET/CT in the diagnosis and prognosis of medullary thyroid cancer (MTC). The study analyzed data from 109 MTC patients who underwent [18F]F-DOPA PET/CT scans between 2008 and 2023. The results showed that [18F]F-DOPA PET/CT had a high diagnostic accuracy for detecting tumor lesions, with a sensitivity of 65% and a specificity of 99%. The study also found that certain PET/CT parameters, such as SUVmean and MTV, were associated with overall survival in MTC patients. Overall, the study concluded that [18F]F-DOPA PET/CT is a valuable tool for both diagnosis and prognosis assessment in MTC patients. [Extracted from the article]

A recent study conducted by researchers at Maltepe University in Istanbul, Turkey, has found that elevated levels of procalcitonin (PCT) can occur in both bacterial infections and medullary thyroid carcinoma (MTC). MTC is a rare form of thyroid cancer that originates from parafollicular cells. The study highlights the importance of PCT and carcinoembryonic antigen (CEA) as biomarkers for diagnosing and monitoring MTC, as elevated levels of these markers can indicate the presence of the disease. Integrating PCT and CEA measurements into routine clinical practice can improve detection, provide insights into therapeutic responses, and aid in the management of MTC. [Extracted from the article]

Researchers at Ordine Mauriziano Hospital in Turin, Italy have conducted a study on medullary thyroid carcinoma (MTC), a type of thyroid cancer. The study aimed to determine if preoperative neck ultrasound combined with pathological data could impact the outcome of MTC. The researchers analyzed data from MTC patients diagnosed between 2000 and 2021 and found that disease-free survival was significantly different based on staging, capsular status, and neck ultrasound. They concluded that preoperative neck ultrasound can help predict the outcome of MTC. This information is important for individuals researching MTC and its prognosis. [Extracted from the article]

A recent study conducted by researchers at the University Health Center examined the long-term survival outcomes of systemic therapy in patients with isolated and mixed medullary thyroid cancer (MTC). The study found that there was no significant difference in overall survival between isolated and mixed MTC. However, systemic therapy was associated with improved survival in isolated MTC but not in the mixed subtype. These findings suggest the need for further investigation and may inform tailored management strategies for mixed MTC. The study was published in the journal Heliyon. [Extracted from the article]

A new report from Villejuif, France presents fresh data on medullary thyroid cancer. The study investigated the safety and efficacy of nintedanib, a triple-angiokinase inhibitor, as a second-line therapy for patients with differentiated or medullary thyroid cancer that had progressed after first-line therapy. The study found that nintedanib did not show a clinically significant improvement in progression-free survival compared to a placebo for patients with pretreated thyroid cancer. Adverse events were more common in patients receiving nintedanib. Further research is needed in this area. [Extracted from the article]

A recent study conducted at Tianjin Medical University Cancer Institute and Hospital in China investigated the expression and prognostic value of Aurora kinase A (AURKA) and tumor-infiltrating lymphocytes (TILs) in medullary thyroid carcinoma (MTC). The researchers collected surgical specimens and clinical data from 137 MTC patients and found that high expression of AURKA combined with low numbers of TILs was an independent prognostic factor for biochemical recurrence and recurrence-free survival. The combination of AURKA and TILs improved the prognostic value for MTC recurrence. The study concluded that the combination of AURKA and TILs could serve as a novel independent prognostic marker for MTC, accurately predicting incurable disease recurrence. [Extracted from the article]

A case report from the University of Utah discusses the incidental detection of multiple endocrine neoplasia and medullary thyroid carcinoma in a man with a history of obesity and hypothyroidism. The patient planned to start taking a Glucagon-like peptide-1 (GLP-1) agonist for weight loss, but prior to starting the drug, a calcitonin level was checked and found to be elevated. Further testing revealed medullary thyroid carcinoma and a genetic mutation confirming the diagnosis of multiple endocrine neoplasia 2 syndrome. The patient's relatives also underwent genetic testing. This case highlights the importance of evaluating patients for underlying conditions before starting certain medications. [Extracted from the article]

A recent study conducted by researchers at Sichuan University in China examined the survival outcomes of patients with medullary thyroid cancer (MTC) based on age cutoffs. The study analyzed data from 3,601 MTC patients from 2000 to 2018 and found a correlation between age and the risk of overall death. The researchers identified age cutoffs at 45 and 60, and each further advanced age cutoff resulted in an increase in MTC-specific death risks and non-MTC-specific death risks. The study highlights the well-defined survival outcome disparity across age cutoffs for MTC. [Extracted from the article]

A new report from Milan, Italy provides fresh data on medullary thyroid cancer (MTC). MTC accounts for only 3% of all thyroid carcinomas, with 75% being sporadic MTC (sMTC) and 25% being hereditary MTC (hMTC) in the context of multiple endocrine neoplasia type 2 (MEN2). Early diagnosis is possible through the determination of the tumor marker calcitonin (Ctn) and the detection of the mutation in the proto-oncogene RET in MEN2 families. Treatment options include surgery and tyrosine kinase inhibitors, depending on the stage of the cancer. The research emphasizes the importance of follow-up care and monitoring for tumor progression. [Extracted from the article]

A recent study conducted by researchers at the University of California Los Angeles (UCLA) has focused on medullary thyroid carcinoma (MTC), a type of thyroid cancer that is responsible for over 10% of deaths related to thyroid cancer. The study aimed to determine whether calcitonin levels can be used as a reliable method for risk-stratifying MTC without lymph node involvement. The researchers concluded that further investigation is needed to determine if calcitonin levels can guide prophylactic neck dissection in sporadic MTC. This research has been peer-reviewed and published in The Laryngoscope. [Extracted from the article]

A recent report from researchers at Royal North Shore Hospital in Sydney, Australia, discusses the case of a 22-year-old woman with metastatic medullary thyroid cancer (MTC) who experienced a rare complication following treatment with the tyrosine kinase inhibitor selpercatinib. The patient developed pulmonary Langerhans cell histiocytosis (LCH), a clonal histiocytic neoplasm usually driven by somatic BRAF mutations. The researchers hypothesize that the selective pressure from RET blockade may have activated a downstream somatic BRAF mutation, resulting in the development of LCH. They recommend continued vigilance for neoplasms driven by dysregulated downstream MAPK signaling in patients undergoing selective RET inhibition. [Extracted from the article]

A recent study conducted at the University of Chicago Medicine examined the recurrence and metastatic spread of medullary thyroid cancer (MTC). The study included 68 patients who underwent surgery for MTC, with a mean age of 54.9 years and 65% of them being female. The study found that male gender, lateral neck node metastasis, and high/highest MTC risk level mutations were significantly associated with recurrence. Preoperative calcitonin levels above 2175 pg/mL were indicative of advanced disease. The study concluded that one in four patients who undergo surgery for MTC will experience recurrence, and further evaluation should be prompted by high preoperative calcitonin levels. [Extracted from the article]

A recent study conducted by researchers at Tianjin Medical University Cancer Institute and Hospital focused on medullary thyroid carcinoma (MTC), a rare malignant tumor. The study aimed to identify the time kinetics and risk factors associated with calcitonin normalization (CN) and biochemical persistence/recurrence (BP) in MTC patients. The study found that achieving CN within one week or one month after surgery was associated with better outcomes, while failure to achieve CN led to biochemical persistence/recurrence and structural recurrence. The study also identified certain predictors of CN and BP, such as lymph node ratio (LNR) and gender. The findings suggest that early changes in calcitonin levels can provide real-time prognostic information for MTC patients. [Extracted from the article]

The University of Pennsylvania has been granted a patent for a treatment for medullary thyroid carcinoma (MTC), a type of thyroid cancer. The treatment involves the use of a chimeric antigen receptor (CAR) that targets a specific cell-surface receptor. The patent provides detailed information on the structure and composition of the CAR polypeptide, which is designed to be an effective therapy for MTC. This invention addresses the need for improved treatments for MTC, which has a high risk of recurrence and limited response to current therapies. [Extracted from the article]

A new report from Hospital Salvador in Santiago, Chile provides fresh data on medullary thyroid cancer (MTC). The researchers present a case study of a 49-year-old male patient with MTC who underwent total thyroidectomy and bilateral dissection. The patient had a follow-up period of six years with undetectable levels of calcitonin, but eventually experienced a rise in markers and was found to have liver metastases. The researchers conclude that while clinical guidelines are useful, they should be applied on a case-by-case basis, as strictly following the guidelines in this case would have resulted in the missed detection of liver metastases. [Extracted from the article]

A study conducted at the University of Texas MD Anderson Cancer Center examined the association between somatic mutations and clinicopathologic behavior in patients with sporadic medullary thyroid cancer (sMTC). The study used next-generation sequencing (NGS) to identify somatic mutations in 191 sMTC tumors. The results showed that somatic RET mutations, including RET M918T, did not have a negative impact on disease-specific survival (DSS) or overall survival (OS) in these patients. The study concluded that somatic RET mutations identified through clinically motivated NGS do not indicate compromised DSS or OS in sMTC patients. [Extracted from the article]

A recent study conducted in Heilongjiang, People's Republic of China, focused on the role of a long non-coding RNA (lncRNA) called ZFAS1 in medullary thyroid carcinoma (MTC). The researchers found that ZFAS1 promotes the invasion of MTC by upregulating the expression of a protein called EPAS1 through the miR-214-3p/UCHL1 axis. Silencing ZFAS1 inhibited MTC cell proliferation and invasion, and reduced EPAS1 protein levels. The study suggests that targeting ZFAS1 could be a potential therapeutic strategy for MTC. [Extracted from the article]

Researchers from Binzhou Medical University in China have conducted a retrospective study on medullary thyroid carcinoma (MTC), a rare form of thyroid cancer. The study aimed to analyze the relationship between calcitonin (Ctn) levels at different time points in MTC patients and evaluate its predictive effect on recurrence. The study included 212 patients with a median follow-up time of 59.5 months. The findings showed that normalization of postoperative serum Ctn at the first month (NPS) was a better predictor of long-term biochemical cure for MTC than preoperative Ctn levels. Non-biochemical cure, larger tumor size, and multifocality were identified as unfavorable independent predictors of structural recurrence and disease-free survival. The study also found no difference in prognosis between different surgeries for sporadic MTC confined to the thyroid lobe. [Extracted from the article]

A recent report from the University of Padua in Italy discusses the role of procalcitonin (ProCt) in the follow-up of medullary thyroid cancer (MTC). The study found that ProCt and calcitonin (Ct) values were highly correlated, and ProCt may be useful as an adjunct to Ct in determining the presence or absence of structural disease in MTC patients. The research suggests that ProCt has a high negative predictive value (NPV) for detecting structural disease. Further research is needed to explore the potential of ProCt in MTC follow-up. [Extracted from the article]